source
- Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancerKaryopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint. The failure represents the company's second unsuccessful attempt to expa…
- FDA approves first freeze-dried plasma product for U.S. useThe FDA has licensed Ezplaz Freeze Dried Plasma (FDP), marking the first freeze-dried plasma product cleared for use in the United States. The product is intended for adult patients who need plasm…